Nonpathologic Infection of Macaques by an Attenuated Mycobacterial Vaccine Is Not Reactivated in the Setting of HIV Co-Infection.

[1]  F. Gleeson,et al.  Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations , 2016, Tuberculosis.

[2]  W. Jacobs,et al.  CD4+ T-cell–independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection , 2016, Proceedings of the National Academy of Sciences.

[3]  D. Lauffenburger,et al.  A Functional Role for Antibodies in Tuberculosis , 2016, Cell.

[4]  A. Sette,et al.  The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans. , 2015, Tuberculosis.

[5]  F. Spertini,et al.  Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. , 2015, The Lancet. Respiratory medicine.

[6]  A. Lackner,et al.  Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis , 2015, Nature Communications.

[7]  Josh Eckels,et al.  A tuberculosis ontology for host systems biology. , 2015, Tuberculosis.

[8]  M. Eibl,et al.  Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. , 2015, Immunotherapy.

[9]  T. Niu,et al.  The DosR Regulon Modulates Adaptive Immunity and Is Essential for Mycobacterium tuberculosis Persistence. , 2015, American journal of respiratory and critical care medicine.

[10]  W. Busey,et al.  Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. , 2015, The American review of respiratory disease.

[11]  H. McShane,et al.  Aerosol immunisation for TB: matching route of vaccination to route of infection , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  S. Morris,et al.  Intranasal Administration of Mycobacterium bovis BCG Induces Superior Protection against Aerosol Infection with Mycobacterium tuberculosis in Mice , 2014, Clinical and Vaccine Immunology.

[13]  A. Lackner,et al.  Aerosol Vaccination with AERAS-402 Elicits Robust Cellular Immune Responses in the Lungs of Rhesus Macaques but Fails To Protect against High-Dose Mycobacterium tuberculosis Challenge , 2014, The Journal of Immunology.

[14]  M. Selman,et al.  S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. , 2013, American journal of respiratory and critical care medicine.

[15]  A. Lackner,et al.  Granuloma correlates of protection against tuberculosis and mechanisms of immune modulation by Mycobacterium tuberculosis. , 2013, Journal of Infectious Diseases.

[16]  M. Selman,et al.  CXCR5⁺ T helper cells mediate protective immunity against tuberculosis. , 2013, The Journal of clinical investigation.

[17]  W. Hinrichs,et al.  Pulmonary vaccine delivery: a realistic approach? , 2012, Journal of aerosol medicine and pulmonary drug delivery.

[18]  A. Lackner,et al.  The non‐human primate model of tuberculosis , 2012, Journal of medical primatology.

[19]  S. Kaufmann,et al.  Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? , 2012, PLoS pathogens.

[20]  W. Jacobs,et al.  BCG: myths, realities, and the need for alternative vaccine strategies. , 2012, Tuberculosis.

[21]  M. Kuroda,et al.  The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs. , 2012, The Journal of infectious diseases.

[22]  D. Kaushal,et al.  Faithful Experimental Models of Human Mycobacterium Tuberculosis Infection , 2012, Mycobacterial diseases : tuberculosis & leprosy.

[23]  J. Blanchard,et al.  Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus , 2011, Journal of medical primatology.

[24]  K. Mansfield,et al.  Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. , 2011, Vaccine.

[25]  L. Kaminskas,et al.  New developments in dry powder pulmonary vaccine delivery. , 2011, Trends in biotechnology.

[26]  D. Kaushal,et al.  Transcriptional Reprogramming in Nonhuman Primate (Rhesus Macaque) Tuberculosis Granulomas , 2010, PloS one.

[27]  Nicholas A. Be,et al.  Genetic requirements for the survival of tubercle bacilli in primates. , 2010, The Journal of infectious diseases.

[28]  A. Haase,et al.  A technique to simultaneously visualize virus-specific CD8+ T cells and virus-infected cells in situ. , 2009, Journal of visualized experiments : JoVE.

[29]  B. Haynes,et al.  Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. , 2009, Vaccine.

[30]  D. Kaushal,et al.  Functional Genomics Reveals Extended Roles of the Mycobacterium tuberculosis Stress Response Factor σH , 2009, Journal of bacteriology.

[31]  A. Hickey,et al.  Preparation and in Vivo Evaluation of a Dry Powder for Inhalation of Capreomycin , 2008, Pharmaceutical Research.

[32]  B. Bloom,et al.  Immunization by a bacterial aerosol , 2008, Proceedings of the National Academy of Sciences.

[33]  R. Gie,et al.  BCG and HIV reconsidered: moving the research agenda forward. , 2007, Vaccine.

[34]  Helen A Fletcher,et al.  Correlates of immune protection from tuberculosis. , 2007, Current molecular medicine.

[35]  A. Hickey,et al.  Pulmonary vaccine delivery , 2007, Expert review of vaccines.

[36]  R. Gie,et al.  The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. , 2007, Vaccine.

[37]  Bing Chen,et al.  Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. , 2006, Vaccine.

[38]  R. Gie,et al.  Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  P. Andersen,et al.  The success and failure of BCG — implications for a novel tuberculosis vaccine , 2005, Nature Reviews Microbiology.

[40]  William R. Jacobs,et al.  Protection Elicited by a Double Leucine and Pantothenate Auxotroph of Mycobacterium tuberculosis in Guinea Pigs , 2004, Infection and Immunity.

[41]  Bing Chen,et al.  A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis , 2002, Nature Medicine.

[42]  R. Fleischmann,et al.  Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative σ factor, SigH , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  N. Letvin,et al.  Disseminated granulomatous disease in a simian immunodeficiency virus- and bacille Calmette-Guèrin-infected rhesus monkey. , 1997, AIDS.

[44]  S. Behar,et al.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity. , 2006, Critical reviews in immunology.